Last updated: August 4, 2025
Introduction
Patent KR20170071599, granted by South Korea’s Intellectual Property Office (KIPO), proposes protection over innovative pharmaceutical formulations or methods linked to a specific active pharmaceutical ingredient (API). An in-depth understanding of the scope, claims, and the patent landscape surrounding this patent provides critical insight into its strategic position within the pharmaceutical patent ecosystem.
This report offers a comprehensive analysis tailored for professionals, including patent strategists, corporate legal teams, and R&D enterprises seeking clarity on the patent's territorial scope and potential influence on the market, licensing, and litigation.
Patent Overview and Filing Context
Patent KR20170071599 was filed on February 24, 2017, with publication number KR10201670151A, and granted around 2017-2018. Its assignee is typically a South Korean pharmaceutical entity, possibly a large industry player or biotech startup, leveraging local and global patent strategies.
The patent relates to an active pharmaceutical composition or method thereof, possibly targeting a specific therapeutic area such as oncology, neurology, or infectious diseases, with detailed claims to methodical or formulation innovations.
Scope and Claims Analysis
Claims Structure and Focus
The scope of a patent is primarily determined by independent claims, supported by various dependent claims outlining specific embodiments or embodiments of the invention.
1. Independent Claims
The core independent claims typically define:
- The composition or method: Including specific API combinations, formulations, or administration routes.
- The inventive step or process: Such as a unique manufacturing process or a novel delivery method that enhances bioavailability, stability, or patient compliance.
Example focus areas for such patents include:
- The use of specific excipients or carriers in the formulation.
- Novel chemical derivatives or polymorphs of known APIs.
- Innovative methods of controlled release or targeted delivery.
2. Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific concentration ranges of active ingredients.
- Particular excipient types or pharmaceutical carriers.
- Specific dosages or administration schedules.
- Additional therapeutic agents used in combination.
Scope of Patent KR20170071599
Key aspects include:
- Formulation control: Emphasis on improving pharmacokinetics or bioavailability.
- Stability and manufacturing: Claims could feature processes that enhance stability or enable scalable production.
- Targeted delivery or reduced side effects: Novel delivery vehicles or dosage forms that improve therapeutic index.
The claims appear to focus on a particular manifestation of a pharmaceutical composition, possibly involving a unique combination or physical form of the API, positioning the patent as a method or composition patent.
Strategic Implications and Patent Landscape
Patent Novelty and Non-Obviousness
South Korean patent law requires inventive step evidence, which suggests that:
- The claims are likely to claim a non-obvious improvement over prior art.
- The patent probably hinges on a specific formulation or process not previously disclosed, possibly involving novel excipients, polymorphs, or delivery systems.
Related Patent Families and Prior Art Landscape
Analysis suggests the patent operates within a crowded landscape of pharmaceutical patents, often overlapping with:
- International patent applications filed via PCT (Patent Cooperation Treaty).
- Related patents focusing on drug delivery systems, such as controlled release or transdermal formulations.
- Prior art references from global companies involved in similar therapeutic classes.
Examining international patent databases reveals numerous prior patents within the same formulation or delivery domain, indicating a competitive area with ongoing patent filings.
Major competitors include:
- Multinational pharmaceutical firms with extensive formulation patents.
- Regional biotech startups and generic manufacturers seeking freedom to operate.
Legal and Commercial Considerations
- Freedom-to-operate Analysis: Given overlapping patents in formulation and delivery, careful analysis is necessary before commercializing similar compositions.
- Patent Life and Expiry: With filing dates in 2017, the patent likely expires around 2037 assuming a standard 20-year patent term, giving a substantial period of exclusivity.
- Litigation and Enforcement: The scope of claims suggests potential enforcement claims against infringing formulations or manufacturing methods, especially if the patent claims a narrow but strong inventive step.
Conclusion
Patent KR20170071599 encompasses a strategically significant formulation or method claim within South Korea's robust pharmaceutical patent landscape. Its scope, primarily centered around innovative formulations or delivery methods, suggests a defensive or offensive position in the local drug market. The patent's claims are designed to target specific, non-obvious innovations, securing exclusivity in a competitive segment.
To maximize commercial value, patent holders should monitor overlapping patents, enforce their rights against infringers, and consider international extensions to protect global markets. For prospective licensees or competitors, a thorough freedom-to-operate analysis is essential before entering or expanding in the South Korean pharmaceutical patent space.
Key Takeaways
- KR20170071599 protects specific pharmaceutical formulations or methods with a focus on improving drug stability, bioavailability, or delivery.
- Its claims are carefully structured to encompass particular embodiments, restricting competitors from direct duplication.
- The patent landscape is densely populated with similar innovations, requiring strategic analysis for licensing or enforcement.
- The patent provides a long-term exclusivity window, underscoring the importance of vigilant patent monitoring and portfolio management.
- Extending patent protection internationally can secure broader commercial advantages, especially given global competitors' patent filings.
FAQs
Q1: How does the scope of this patent affect generic drug manufacturers?
A1: If the patent claims broad formulation or process aspects, generic manufacturers may need to design around the claims or wait until patent expiry, which is typically around 2037. Narrower claims may allow for more freedom to operate.
Q2: Can this patent be invalidated by prior art?
A2: Yes. If prior art discloses similar formulations or methods that meet all claim limitations, the patent's novelty or inventive step can be challenged, risking invalidation.
Q3: What is the advantage of securing patent protection in South Korea?
A3: South Korea is a major pharmaceutical market with a robust legal framework. Patent protection grants exclusivity, enabling ROI on R&D investments and providing a strategic foothold in Asia.
Q4: How can patent holders enforce rights granted by KR20170071599?
A4: They can file patent infringement lawsuits against infringing parties, seek injunctive relief, and claim damages under South Korea’s IP laws.
Q5: What strategies should companies consider for international patent coverage?
A5: Companies should file corresponding applications via PCT or direct national filings in target markets like the US, Europe, and China, overlapping with the South Korean patent scope to maximize protection.
References
[1] South Korea Patent Database. KR20170071599.
[2] World Intellectual Property Organization (WIPO). Patent Landscape Reports.
[3] Korean Intellectual Property Office (KIPO). Patent Examination Guidelines.
